248 related articles for article (PubMed ID: 24598841)
1. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
[TBL] [Abstract][Full Text] [Related]
2. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
3. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
4. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
Zipperer E; Post JG; Herkert M; Kündgen A; Fox F; Haas R; Gattermann N; Germing U
Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
[TBL] [Abstract][Full Text] [Related]
5. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
[TBL] [Abstract][Full Text] [Related]
6. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y
Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.
Fertrin KY; Lanaro C; Franco-Penteado CF; de Albuquerque DM; de Mello MR; Pallis FR; Bezerra MA; Hatzlhofer BL; Olbina G; Saad ST; da Silva Araújo A; Westerman M; Costa FF
Am J Hematol; 2014 Apr; 89(4):385-90. PubMed ID: 24860871
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
9. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
10. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.
Finkenstedt A; Bianchi P; Theurl I; Vogel W; Witcher DR; Wroblewski VJ; Murphy AT; Zanella A; Zoller H
Br J Haematol; 2009 Mar; 144(5):789-93. PubMed ID: 19120353
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.
Gu S; Song X; Zhao Y; Guo J; Fei C; Xu F; Wu L; Zhang X; Zhao J; Chang C; Li X
Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
13. Iron Status in Newly Diagnosed
Susanah S; Rakhmilla LE; Ghozali M; Trisaputra JO; Moestopo O; Sribudiani Y; Idjradinata PS; Maskoen AM
Biomed Res Int; 2021; 2021():5560319. PubMed ID: 33954177
[TBL] [Abstract][Full Text] [Related]
14. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.
Ambaglio I; Malcovati L; Papaemmanuil E; Laarakkers CM; Della Porta MG; Gallì A; Da Vià MC; Bono E; Ubezio M; Travaglino E; Albertini R; Campbell PJ; Swinkels DW; Cazzola M
Haematologica; 2013 Mar; 98(3):420-3. PubMed ID: 23300182
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.
Huang Y; Liu R; Wei X; Liu J; Pan L; Yang G; Lai Y
Biomed Res Int; 2019; 2019():4504302. PubMed ID: 30834265
[TBL] [Abstract][Full Text] [Related]
16. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
Cazzola M; Della Porta MG; Malcovati L
Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
[TBL] [Abstract][Full Text] [Related]
18. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
de Swart L; Reiniers C; Bagguley T; van Marrewijk C; Bowen D; Hellström-Lindberg E; Tatic A; Symeonidis A; Huls G; Cermak J; van de Loosdrecht AA; Garelius H; Culligan D; Macheta M; Spanoudakis M; Panagiotidis P; Krejci M; Blijlevens N; Langemeijer S; Droste J; Swinkels DW; Smith A; de Witte T;
Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
[TBL] [Abstract][Full Text] [Related]
19. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndromes and iron metabolism].
Kawabata H
Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
